{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:11:30Z","timestamp":1789056690991,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for the treatment of generalized myasthenia gravis (gMG). Evidence describing large-scale cohorts in routine United States (US) practice remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living (MG-ADL) outcomes among a US cohort enrolled in the My VYVGART Path patient support program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed adults with gMG who initiated efgartigimod on or before December 31, 2025, and had a baseline (pre-efgartigimod) MG-ADL score recorded and \u22654 follow-up assessments available. Outcomes included dosing interval distributions, longitudinal MG-ADL trends, durability of clinically meaningful improvement (CMI; \u22652-point reduction), and best observed response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3,326 eligible patients (mean [SD] baseline MG-ADL: 8.2 [3.8]; mean [SD] treatment duration: 18.0 [11.0] months), the most common inter-cycle interval length was 4\u202fweeks, though intervals ranged widely, reflecting individualized care. Patients achieved rapid and sustained clinical improvement, with mean MG-ADL improvement of 3.3 points by Month 1 and 4.5 points by Month 18. Of 2,964 patients achieving CMI, the majority (&amp;gt;75%) maintained CMI for &amp;gt;80% of their available follow-up time. Best observed response analyses showed a mean (SD) improvement from baseline of 5.9 (3.5) points, with 83% achieving MG-ADL score \u22644 and 47% achieving minimal symptom expression (MG-ADL score 0\u20131).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this large and diverse US cohort, efgartigimod was administered using both proactive (structured) and individualized (flexible) dosing strategies, leading to rapid, deep, and sustained clinically meaningful improvements. These findings support efgartigimod as an effective and adaptable therapy for gMG in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1881758","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:03:48Z","timestamp":1785416628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database"],"prefix":"10.3389","volume":"17","author":[{"given":"Pushpa","family":"Narayanaswami","sequence":"first","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center\/Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Gordon","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Neurology, Virginia Commonwealth University","place":["Richmond, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratna","family":"Bhavaraju-Sanka","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Health Science Center at San Antonio","place":["San Antonio, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Qi","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jefferson","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Aldridge","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Heerlein","sequence":"additional","affiliation":[{"name":"argenx","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[{"name":"Department of Neurology, UNC School of Medicine","place":["Chapel Hill, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Dhingra","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["Gurugram, Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit R.","family":"Menon","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["Bengaluru, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo","place":["Buffalo, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","article-title":"New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making","volume":"39","author":"Gerischer","year":"2025","journal-title":"BioDrugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"17562864251398375","DOI":"10.1177\/17562864251398375","article-title":"Appropriate use of steroids for patients with generalized myasthenia gravis: an international Delphi study","volume":"18","author":"Wiendl","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/brainsci15090978","article-title":"Immunological targets in generalized myasthenia gravis treatment: where are we going now?","volume":"15","author":"Rossini","year":"2025","journal-title":"Brain Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"Binks","year":"2025","journal-title":"J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/biomedicines13122975","article-title":"Efgartigimod for generalized myasthenia gravis and beyond: a narrative review of its pharmacological profile, clinical utility, and expanding applications","volume":"13","author":"Mansour","year":"2025","journal-title":"Biomedicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1755374","DOI":"10.3389\/fneur.2026.1755374","article-title":"Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus","volume":"17","author":"Tsokkos","year":"2026","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e200276","DOI":"10.1212\/cpj.0000000000200276","article-title":"Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan","volume":"14","author":"Suzuki","year":"2024","journal-title":"Neurol Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"17562864241311127","DOI":"10.1177\/17562864241311127","article-title":"Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study","volume":"18","author":"Zhu","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mus.28003","article-title":"Single institution experience with efgartigimod in patients with myasthenia gravis: patient selection, dosing schedules, treatment response, and adverse events","volume":"69","author":"Singer","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e16189","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center","volume":"31","author":"Frangiamore","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref20","year":"2025"},{"key":"ref21","year":"2025"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","article-title":"Utilization of MG-ADL in myasthenia gravis clinical research and care","volume":"65","author":"Muppidi","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.28334","article-title":"Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single Center","volume":"71","author":"Silvestri","year":"2025","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/acn3.70051","article-title":"ADAPT NXT: fixed cycles or every-other-week IV efgartigimod in generalized myasthenia gravis","volume":"12","author":"Habib","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e70563","DOI":"10.1111\/ene.70563","article-title":"Minimal symptom expression in generalized myasthenia gravis: a valuable patient-centric treatment goal","volume":"33","author":"Meisel","year":"2026","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00415-026-13722-3","article-title":"Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study","volume":"273","author":"Oeztuerk","year":"2026","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00415-025-13367-8","article-title":"Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study","volume":"272","author":"Zhu","year":"2025","journal-title":"J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e00730","DOI":"10.1016\/j.neurot.2025.e00730","article-title":"Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: a retrospective cohort study","volume":"22","author":"Guo","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"110587","DOI":"10.1016\/j.clim.2025.110587","article-title":"Efgartigimod versus standard of care in new-onset AChR subtype generalized myasthenia gravis: a prospective cohort study","volume":"281","author":"He","year":"2025","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1881758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:03:49Z","timestamp":1785416629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1881758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":30,"alternative-id":["10.3389\/fneur.2026.1881758"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1881758","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1881758"}}